 | • レポートコード：MRC2012A10356 • 出版社/出版日：GlobalInfoResearch / 2020年12月28日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、潰瘍性大腸炎免疫治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。潰瘍性大腸炎免疫治療薬の種類別市場規模（アダリムマブ、セルトリズマブペゴル、トファシチニブ、エタネルセプト、ゴリムマブ、アバタセプト、インフリキシマブ、その他）、用途別市場規模（関節リウマチ、クローン病（CD）、強直性脊椎炎（AS）、乾癬（Ps）、潰瘍性大腸炎（UC））、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Janssen Biotech, Inc.、Genentech USA, Inc.、UCBCares、Bristol-Myers Squibb Company、Biogen、AbbVie Inc.、Pfizer Inc.、Celltrion Healthcare、AMGEN、ROCHE、 ・地域別グローバル市場分析 2015年-2020年 ・潰瘍性大腸炎免疫治療薬の北米市場（アメリカ、カナダ、メキシコ） ・潰瘍性大腸炎免疫治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・潰瘍性大腸炎免疫治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・潰瘍性大腸炎免疫治療薬の南米市場（ブラジル、アルゼンチン） ・潰瘍性大腸炎免疫治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アダリムマブ、セルトリズマブペゴル、トファシチニブ、エタネルセプト、ゴリムマブ、アバタセプト、インフリキシマブ、その他 ・用途別分析：関節リウマチ、クローン病（CD）、強直性脊椎炎（AS）、乾癬（Ps）、潰瘍性大腸炎（UC） ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Ulcerative Colitis Immunology Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Ulcerative Colitis Immunology Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Ulcerative Colitis Immunology Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Ulcerative Colitis Immunology Drugs market has been segmented into
Adalimumab
Certolizumab Pegol
Tofacitinib
Etanercept
Golimumab
Abatacept
Infliximab
Others
By Application, Ulcerative Colitis Immunology Drugs has been segmented into:
Rheumatoid Arthritis
Crohn’s Disease(CD)
Ankylosing Spondylitis(AS)
Psoriasis(Ps)
Ulcerative Colitis(UC)
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Ulcerative Colitis Immunology Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Ulcerative Colitis Immunology Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Ulcerative Colitis Immunology Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Ulcerative Colitis Immunology Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Ulcerative Colitis Immunology Drugs Market Share Analysis
Ulcerative Colitis Immunology Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Ulcerative Colitis Immunology Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Ulcerative Colitis Immunology Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Ulcerative Colitis Immunology Drugs are:
Janssen Biotech, Inc.
Genentech USA, Inc.
UCBCares
Bristol-Myers Squibb Company
Biogen
AbbVie Inc.
Pfizer Inc.
Celltrion Healthcare
AMGEN
ROCHE
Among other players domestic and global, Ulcerative Colitis Immunology Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ulcerative Colitis Immunology Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ulcerative Colitis Immunology Drugs, with price, sales, revenue and global market share of Ulcerative Colitis Immunology Drugs in 2018 and 2019.
Chapter 3, the Ulcerative Colitis Immunology Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ulcerative Colitis Immunology Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Ulcerative Colitis Immunology Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Ulcerative Colitis Immunology Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Ulcerative Colitis Immunology Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Ulcerative Colitis Immunology Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Adalimumab
1.2.3 Certolizumab Pegol
1.2.4 Tofacitinib
1.2.5 Etanercept
1.2.6 Golimumab
1.2.7 Abatacept
1.2.8 Infliximab
1.2.9 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Ulcerative Colitis Immunology Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Rheumatoid Arthritis
1.3.3 Crohn’s Disease(CD)
1.3.4 Ankylosing Spondylitis(AS)
1.3.5 Psoriasis(Ps)
1.3.6 Ulcerative Colitis(UC)
1.4 Overview of Global Ulcerative Colitis Immunology Drugs Market
1.4.1 Global Ulcerative Colitis Immunology Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Janssen Biotech, Inc.
2.1.1 Janssen Biotech, Inc. Details
2.1.2 Janssen Biotech, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Janssen Biotech, Inc. SWOT Analysis
2.1.4 Janssen Biotech, Inc. Product and Services
2.1.5 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Genentech USA, Inc.
2.2.1 Genentech USA, Inc. Details
2.2.2 Genentech USA, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Genentech USA, Inc. SWOT Analysis
2.2.4 Genentech USA, Inc. Product and Services
2.2.5 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 UCBCares
2.3.1 UCBCares Details
2.3.2 UCBCares Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 UCBCares SWOT Analysis
2.3.4 UCBCares Product and Services
2.3.5 UCBCares Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bristol-Myers Squibb Company
2.4.1 Bristol-Myers Squibb Company Details
2.4.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bristol-Myers Squibb Company SWOT Analysis
2.4.4 Bristol-Myers Squibb Company Product and Services
2.4.5 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Biogen
2.5.1 Biogen Details
2.5.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Biogen SWOT Analysis
2.5.4 Biogen Product and Services
2.5.5 Biogen Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 AbbVie Inc.
2.6.1 AbbVie Inc. Details
2.6.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 AbbVie Inc. SWOT Analysis
2.6.4 AbbVie Inc. Product and Services
2.6.5 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pfizer Inc.
2.7.1 Pfizer Inc. Details
2.7.2 Pfizer Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pfizer Inc. SWOT Analysis
2.7.4 Pfizer Inc. Product and Services
2.7.5 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Celltrion Healthcare
2.8.1 Celltrion Healthcare Details
2.8.2 Celltrion Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Celltrion Healthcare SWOT Analysis
2.8.4 Celltrion Healthcare Product and Services
2.8.5 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 AMGEN
2.9.1 AMGEN Details
2.9.2 AMGEN Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AMGEN SWOT Analysis
2.9.4 AMGEN Product and Services
2.9.5 AMGEN Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 ROCHE
2.10.1 ROCHE Details
2.10.2 ROCHE Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 ROCHE SWOT Analysis
2.10.4 ROCHE Product and Services
2.10.5 ROCHE Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Ulcerative Colitis Immunology Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Ulcerative Colitis Immunology Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Ulcerative Colitis Immunology Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Ulcerative Colitis Immunology Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Ulcerative Colitis Immunology Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Ulcerative Colitis Immunology Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
4.5 South America Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Ulcerative Colitis Immunology Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Ulcerative Colitis Immunology Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Ulcerative Colitis Immunology Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Ulcerative Colitis Immunology Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
6.3 UK Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
6.4 France Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7.5 India Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Ulcerative Colitis Immunology Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Ulcerative Colitis Immunology Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Ulcerative Colitis Immunology Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Ulcerative Colitis Immunology Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Ulcerative Colitis Immunology Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Ulcerative Colitis Immunology Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Ulcerative Colitis Immunology Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Ulcerative Colitis Immunology Drugs Price by Type (2015-2020)
11 Global Ulcerative Colitis Immunology Drugs Market Segment by Application
11.1 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
11.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Ulcerative Colitis Immunology Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Ulcerative Colitis Immunology Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Ulcerative Colitis Immunology Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025)
12.2.2 Europe Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025)
12.2.4 South America Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025)
12.3 Ulcerative Colitis Immunology Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Ulcerative Colitis Immunology Drugs Market Share Forecast by Type (2021-2025)
12.4 Ulcerative Colitis Immunology Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Ulcerative Colitis Immunology Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Ulcerative Colitis Immunology Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Ulcerative Colitis Immunology Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Ulcerative Colitis Immunology Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Janssen Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Major Business
Table 9. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Janssen Biotech, Inc. SWOT Analysis
Table 11. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product and Services
Table 12. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Genentech USA, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Major Business
Table 15. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Genentech USA, Inc. SWOT Analysis
Table 17. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product and Services
Table 18. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. UCBCares Basic Information, Manufacturing Base and Competitors
Table 20. UCBCares Ulcerative Colitis Immunology Drugs Major Business
Table 21. UCBCares Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 22. UCBCares SWOT Analysis
Table 23. UCBCares Ulcerative Colitis Immunology Drugs Product and Services
Table 24. UCBCares Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 26. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Major Business
Table 27. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 28. Bristol-Myers Squibb Company SWOT Analysis
Table 29. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product and Services
Table 30. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Biogen Basic Information, Manufacturing Base and Competitors
Table 32. Biogen Ulcerative Colitis Immunology Drugs Major Business
Table 33. Biogen Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 34. Biogen SWOT Analysis
Table 35. Biogen Ulcerative Colitis Immunology Drugs Product and Services
Table 36. Biogen Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 38. AbbVie Inc. Ulcerative Colitis Immunology Drugs Major Business
Table 39. AbbVie Inc. Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 40. AbbVie Inc. SWOT Analysis
Table 41. AbbVie Inc. Ulcerative Colitis Immunology Drugs Product and Services
Table 42. AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Pfizer Inc. Ulcerative Colitis Immunology Drugs Major Business
Table 45. Pfizer Inc. Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 46. Pfizer Inc. SWOT Analysis
Table 47. Pfizer Inc. Ulcerative Colitis Immunology Drugs Product and Services
Table 48. Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Celltrion Healthcare Basic Information, Manufacturing Base and Competitors
Table 50. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Major Business
Table 51. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 52. Celltrion Healthcare SWOT Analysis
Table 53. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product and Services
Table 54. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. AMGEN Basic Information, Manufacturing Base and Competitors
Table 56. AMGEN Ulcerative Colitis Immunology Drugs Major Business
Table 57. AMGEN Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 58. AMGEN SWOT Analysis
Table 59. AMGEN Ulcerative Colitis Immunology Drugs Product and Services
Table 60. AMGEN Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. ROCHE Basic Information, Manufacturing Base and Competitors
Table 62. ROCHE Ulcerative Colitis Immunology Drugs Major Business
Table 63. ROCHE Ulcerative Colitis Immunology Drugs Total Revenue (USD Million) (2017-2018)
Table 64. ROCHE SWOT Analysis
Table 65. ROCHE Ulcerative Colitis Immunology Drugs Product and Services
Table 66. ROCHE Ulcerative Colitis Immunology Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Ulcerative Colitis Immunology Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 68. Global Ulcerative Colitis Immunology Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Ulcerative Colitis Immunology Drugs Sales by Regions (2015-2020) (K Pcs)
Table 70. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Regions (2015-2020)
Table 71. Global Ulcerative Colitis Immunology Drugs Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Ulcerative Colitis Immunology Drugs Sales by Countries (2015-2020) (K Pcs)
Table 73. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2015-2020)
Table 74. North America Ulcerative Colitis Immunology Drugs Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020)
Table 76. Europe Ulcerative Colitis Immunology Drugs Sales by Countries (2015-2020) (K Pcs)
Table 77. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2015-2020)
Table 78. Europe Ulcerative Colitis Immunology Drugs Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Regions (2015-2020) (K Pcs)
Table 80. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Ulcerative Colitis Immunology Drugs Sales by Countries (2015-2020) (K Pcs)
Table 83. South America Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2015-2020)
Table 84. South America Ulcerative Colitis Immunology Drugs Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Ulcerative Colitis Immunology Drugs Sales by Countries (2015-2020) (K Pcs)
Table 87. Middle East & Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Ulcerative Colitis Immunology Drugs Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020)
Table 90. Global Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 91. Global Ulcerative Colitis Immunology Drugs Sales Share by Type (2015-2020)
Table 92. Global Ulcerative Colitis Immunology Drugs Revenue by Type (2015-2020) (USD Million)
Table 93. Global Ulcerative Colitis Immunology Drugs Revenue Share by Type (2015-2020)
Table 94. Global Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 95. Global Ulcerative Colitis Immunology Drugs Sales Share by Application (2015-2020)
Table 96. Global Ulcerative Colitis Immunology Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 97. Global Ulcerative Colitis Immunology Drugs Market Share Forecast by Regions (2021-2025)
Table 98. Global Ulcerative Colitis Immunology Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 99. Global Ulcerative Colitis Immunology Drugs Market Share Forecast by Type (2021-2025)
Table 100. Global Ulcerative Colitis Immunology Drugs Sales Forecast by Application (2021-2025)
Table 101. Global Ulcerative Colitis Immunology Drugs Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Ulcerative Colitis Immunology Drugs Picture
Figure 2. Global Sales Market Share of Ulcerative Colitis Immunology Drugs by Type in 2019
Figure 3. Adalimumab Picture
Figure 4. Certolizumab Pegol Picture
Figure 5. Tofacitinib Picture
Figure 6. Etanercept Picture
Figure 7. Golimumab Picture
Figure 8. Abatacept Picture
Figure 9. Infliximab Picture
Figure 10. Others Picture
Figure 11. Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2018
Figure 12. Rheumatoid Arthritis Picture
Figure 13. Crohn's Disease(CD) Picture
Figure 14. Ankylosing Spondylitis(AS) Picture
Figure 15. Psoriasis(Ps) Picture
Figure 16. Ulcerative Colitis(UC) Picture
Figure 17. Global Ulcerative Colitis Immunology Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 18. United States Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Canada Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Mexico Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Germany Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. France Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. UK Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Russia Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Italy Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. China Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Japan Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Korea Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. India Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Southeast Asia Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Australia Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 32. Brazil Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Egypt Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Saudi Arabia Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 35. South Africa Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 36. Turkey Ulcerative Colitis Immunology Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 37. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Manufacturer in 2019
Figure 38. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Manufacturer in 2019
Figure 39. Top 3 Ulcerative Colitis Immunology Drugs Manufacturer (Revenue) Market Share in 2019
Figure 40. Top 6 Ulcerative Colitis Immunology Drugs Manufacturer (Revenue) Market Share in 2019
Figure 41. Key Manufacturer Market Share Trend
Figure 42. Global Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 43. Global Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Regions (2015-2020)
Figure 45. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Regions in 2018
Figure 46. North America Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
Figure 47. Europe Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
Figure 48. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
Figure 49. South America Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
Figure 50. Middle East & Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020)
Figure 51. North America Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2015-2020)
Figure 53. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Countries in 2018
Figure 54. North America Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 55. North America Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2018
Figure 56. United States Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. Canada Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Mexico Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Europe Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020)
Figure 61. Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2019
Figure 62. Germany Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. UK Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. France Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Russia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Italy Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Regions 2019
Figure 69. Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue Market Share by Regions 2019
Figure 70. China Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Japan Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Korea Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. India Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 74. Southeast Asia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. South America Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 76. South America Ulcerative Colitis Immunology Drugs Sales Market Share by Countries in 2019
Figure 77. South America Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2019
Figure 78. Brazil Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Argentina Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 81. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Countries in 2019
Figure 82. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2015-2020)
Figure 83. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2019
Figure 84. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 85. Egypt Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 86. Turkey Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 87. South Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 88. Global Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 89. Global Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 90. North America Sales Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025) (K Pcs)
Figure 91. Europe Sales Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025) (K Pcs)
Figure 92. Asia-Pacific Sales Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025) (K Pcs)
Figure 93. South America Sales Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025) (K Pcs)
Figure 94. Middle East & Africa Sales Ulcerative Colitis Immunology Drugs Market Forecast (2021-2025) (K Pcs)
Figure 95. Sales Channel: Direct Channel vs Indirect Channel
潰瘍性大腸炎免疫薬 の世界市場（～2026年） Market Analysis and Insights: Global Ulcerative Colitis Immunology Drugs Market The global Ulcerative Colitis Immunology Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ulcerative Colitis Immunology Drugs Scope a…- 潰瘍性大腸炎の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Ulcerative Colitis market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ulcerative Colitis market …
- 潰瘍性大腸炎治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Ulcerative Colitis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ulcerative Colit…
- 潰瘍性大腸炎治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Drug for Ulcerative Colitis market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Drug for Ulcerati…
- レミケード（インフリキシマブ）医薬品の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Remicade (infliximab) Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Remicade (inflixim…